A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Scott Olson | Getty ImagesEli...
Eli Lilly on Wednesday said it will halt development of its Alzheimer's treatment candidate solanezumab after the antibody failed to slow disease progression.Solanezumab's failure...
